Alpha-Emitting Radionuclides: Current Status and Future Perspectives.
Matthias MiedererMartina Benešová-SchäferConstantin MamatDavid KästnerMarc PretzeEnrico MichlerClaudia BrogsitterJörg KotzerkeKlaus KopkaDavid A ScheinbergMichael R McDevittPublished in: Pharmaceuticals (Basel, Switzerland) (2024)
The use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation qualities is an important factor in understanding and implementing new therapies. Together with the combined approach of imaging and therapy, therapeutic nuclear medicine has recently made great progress. A particular area of research is the use of alpha-emitting radionuclides, which have unique physical properties associated with outstanding advantages, e.g., for single tumor cell targeting. Here, recent results and open questions regarding the production of alpha-emitting isotopes as well as their chemical combination with carrier molecules and clinical experience from compassionate use reports and clinical trials are discussed.
Keyphrases
- quantum dots
- clinical trial
- fluorescent probe
- current status
- energy transfer
- cancer therapy
- high resolution
- single cell
- physical activity
- palliative care
- light emitting
- cell therapy
- stem cells
- radiation therapy
- emergency department
- adverse drug
- electronic health record
- photodynamic therapy
- open label
- double blind
- drug induced